Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Rhea-AI Summary

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology firm, announced that CFO Anthony H. Kim will present at two investor conferences in March 2022. The first is the ROTH Annual Conference on March 14 at 11:00 a.m. ET, followed by the Oppenheimer Virtual Annual Healthcare Conference on March 17 at 10:40 a.m. ET. Webcasts of both presentations will be available on the company's website. Marker is focused on developing non-engineered, tumor-specific T cell therapies for hematological malignancies and solid tumors.

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Anthony H. Kim, Chief Financial Officer of Marker Therapeutics, will present at two upcoming investor conferences in March.

Conference Details

ROTH Annual Conference
Fireside Chat
Date: Monday, March 14, 2022
Time: 11:00 a.m. ET

Oppenheimer Virtual Annual Healthcare Conference
Presentation
Date: Thursday, March 17, 2022
Time: 10:40 a.m. ET

Webcasts of the presentations will be accessible in the Investors section of the Company’s website at markertherapeutics.com and will be available for replay following the events.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Investors and Media Contacts

Marker Therapeutics:

Neda Safarzadeh
Vice President/Head of Investor Relations, PR & Marketing
(713) 400-6451
Investor.Relations@markertherapeutics.com

Solebury Trout:

Media
Amy Bonanno
Abonanno@soleburytrout.com

FAQ

What date will Marker Therapeutics present at the ROTH Annual Conference?

Marker Therapeutics will present at the ROTH Annual Conference on March 14, 2022.

What time is the Oppenheimer Virtual Annual Healthcare Conference presentation?

The Oppenheimer Virtual Annual Healthcare Conference presentation is scheduled for March 17, 2022, at 10:40 a.m. ET.

Where can I access the webcasts of Marker Therapeutics' presentations?

Webcasts of Marker Therapeutics' presentations will be accessible on the Investors section of their website.

What is the focus of Marker Therapeutics' immunotherapy development?

Marker Therapeutics specializes in next-generation T cell-based immunotherapies for hematological malignancies and solid tumors.

What technology does Marker Therapeutics use for its T cell therapies?

Marker Therapeutics uses a technology based on the selective expansion of non-engineered, tumor-specific T cells.